NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

TSX · Drug Manufacturers - Specialty & Generic · CAD

Crescita Therapeutics Inc. (CTX.TO) Stock Analysis

Crescita Therapeutics Inc. (CTX.TO) is a Drug Manufacturers - Specialty & Generic stock listed on TSX and quoted in Canadian Dollar.

CTX.TO

CA$0.79

+CA$0.04 (+5.33%)

Last trade June 4, 2026

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CTX.TO with… →

CTX.TO Key Statistics

As of Jun 4, 2026
Trading
Open
CA$0.79
Previous Close
CA$0.75
52-Week Range
0.40–0.77
Volume
1.16K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−0.14
Valuation
Market Cap
CA$13.96M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
0.60
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.01
Financials (FY)
Profit marginThe share of revenue left as profit after all costs and taxes.
−1.38%
1-Year Return
+49.06%
Dividend and dates
Avg Volume
36.24K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

CTX.TO Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+64.58%
2025 (partial year)−18.64%

As of June 4, 2026.

CTX.TO Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 103 stocks
MetricCTX.TODrug Manufacturers - Specialty & Generic medianvs median
P/S ratio0.602.300.3x the median
Profit margin−1.38%−3.14%1.8 pts above

Medians across 103 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

The market values Crescita Therapeutics Inc. (CTX.TO) at CA$13.96M. The company sits in the Healthcare sector, in the Drug Manufacturers - Specialty & Generic industry. Headcount on file is 65.

The most recent close on file for CTX.TO is CA$0.79, dated June 4, 2026. That is +CA$0.04 (+5.33%) against the previous close. Over the past 52 weeks the price has ranged from CA$0.40 to CA$0.77. The latest close sits 97.5% above that 52-week low.

Financial Health

Trailing twelve-month revenue on file is CA$23.22M. Profit margin runs at −1.38%. That is 1.8 percentage points above the Drug Manufacturers - Specialty & Generic median of −3.14%. Trailing earnings per share are −0.01.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 0.6 times revenue. On price-to-sales that is 0.3 times the Drug Manufacturers - Specialty & Generic median of 2.3. The medians here are taken across 103 Drug Manufacturers - Specialty & Generic companies that report the metric.

Over the trailing twelve months the price has returned +49.06%. Beta against the wider market is reported at −0.15. Annualized volatility over the trailing 1 year is 72.42%.

Growth & Income

No dividend is on file for CTX.TO.

2026 is still running; the price is +64.58% year to date.

Peer Comparison

Crescita Therapeutics Inc. (CTX.TO) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Crescita Therapeutics Inc. CTX.TO CA$13.96M —
Takeda Pharmaceutical Company Limited TAK CA$58.92B —
Teva Pharmaceutical Industries Limited TEVA CA$42.37B 60.6
Haleon plc HLN CA$42.22B 20.0

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 19.3x. Crescita Therapeutics Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of June 4, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$58.92B

 TEVA

Teva Pharmaceutical Industries Limited

$42.37B

 HLN

Haleon plc

$42.22B

 ZTS

Zoetis Inc.

$31.33B

 UTHR

United Therapeutics Corporation

$20.91B

 VTRS

Viatris Inc.

$19.39B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Crescita Therapeutics Inc.

Crescita Therapeutics Inc., a dermatology company, provides non-prescription skincare products and prescription drug products in Canada, the United States, and internationally. It operates through three segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. The company owns proprietary drug delivery platforms, which include Multiplexed Molecular Penetration Enhancers and DuraPee that supports the development of patented formulations to facilitate the delivery of active ingredients into or through the skin. The company's prescription products include Pliaglis, a topical local anesthetic cream that provides dermal analgesia on intact skin prior to superficial dermatological procedures. Its non-prescription portfolio offers dermocosmetic products, such as face creams, cleansers, exfoliants, masks, serums, and suncare to treat mild acne, aging, dehydration, pigmentation, sensitivity, and rosacea under the Laboratoire Dr Renaud and Aquafolia brands; and medical aesthetics under the Pro-Derm and Alyria brands for non-invasive and minimally invasive procedures or skincare treatments. The company also distributes Bacti Control, a solution for hand hygiene; NCTF Boost 135 HA, a skin revitalization solution; Obagi Medical products; ART FILLER, a hyaluronic acid-based dermal filler; and MicronJet, an intradermal injection device. The company has commercialization license agreement with Cantabria Labs Inc. Crescita Therapeutics Inc. was incorporated in 2016 and is headquartered in Laval, Canada.

Visit website →